13 Results

People

  1. Scher
    Scher
  2. Fleisher
    Fleisher
  3. Schreiber
    Schreiber
  4. Danila
    Danila
  5. McLaughlin
    McLaughlin
  6. Hullings
    Hullings
  7. Lee
    Lee
  8. Arslan
    Arslan
  9. Bambury
    Bambury
  10. Berger
    Berger

Groups

  1. Department of Medicine (13)
  2. Genitourinary Oncology Service (13)
  3. Solid Tumor Oncology Division (13)
  4. Nursing (4)
  5. Epidemiology and Biostatistics (3)
  6. Computational Oncology Service (2)
  7. GSK Faculty (2)
  8. Human Oncology and Pathogenesis Program (2)
  9. Biostatistics Service (1)
  10. Molecular Imaging and Therapy Service (1)
  1. "Nicole Schreiber"
  2. "Howard Scher"
  3. "American Society of Clinical Oncology"
Formats
  1. Meeting Abstract (13)
Groups
  1. Department of Medicine (13)
  2. Genitourinary Oncology Service (13)
  3. Solid Tumor Oncology Division (13)
  4. Nursing (4)
  5. Epidemiology and Biostatistics (3)
  6. Computational Oncology Service (2)

More Groups

People
  1. Howard Scher (13)
  2. Nicole Schreiber (13)
  3. Martin Fleisher (8)
  4. Brigit McLaughlin (5)
  5. Daniel Danila (5)
  6. Jerry Lee (3)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (2)
  4. 2016 (2)
  5. 2015 (3)
  6. 2014 (1)

More Years

Publications
  1. Journal of Clinical Oncology (13)
Publishers
  1. American Society of Clinical Oncology (13)

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CTC versus biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts)
    Meeting Abstract

    Scher, H. I.; Lee, J.; Dago, A. E.; Barnett, E.; Sutton, R.; Carbone, E.; Schreiber, N. A.; Hullings, M.; Ebrahim, N.; Landers, M. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Unique patterns of the selection and change in circulating tumor cell (CTC) phenotypes and genotypes by drug class in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Schonhoft, J.; Graf, R. P.; Dago, A. E.; Lee, J.; Sutton, R.; Schreiber, N. A.; Hullings, M.; Jendrisak, A.; Wang, Y.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Clonal concordance and genomic heterogeneity in single CTC copy number alterations vs. paired IMPACT metastatic tissue sequencing from mCRPC patient samples
    Meeting Abstract

    Scher, H. I.; Dago, A. E.; Lee, J.; Sutton, R.; Graf, R. P.; Schreiber, N. A.; Hullings, M.; Wang, Y.; Landers, M. A.; Solit, D. B.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Winquist, E.; McLaughlin, B.; Lu, D.; Orr, S.; Fleisher, M.; Lowes, L.; Anderson, A. K. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A)
    Meeting Abstract

    Scher, H. I.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R. P.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx)
    Meeting Abstract

    Dittamore, R. V.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy
    Meeting Abstract

    Scher, H. I.; Graf, R.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Jendrisak, A.; Greene, S.; Rodriguez, A.; Dugan, L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients
    Meeting Abstract

    Scher, H. I.; Graf, R.; Louw, J.; Jendrisak, A.; Johnson, A.; Greene, S.; Rodriguez, A.; Schreiber, N. A.; McLaughlin, B.; Dugan, L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC)
    Meeting Abstract

    Landers, M.; Greene, S.; Schreiber, N. A.; Rodriguez, A.; Bambury, R. M.; Danila, D. C.; Rathkopf, D. E.; Fleisher, M.; Louw, J.; Jendrisak, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Fleisher, M.; Carrasquillo, J. A.; Gilbert, H.; Morris, M. J.; Bellomo, L. P.; Hendrikx, P. J.; Szafer-Glusman, E.; Herkal, A.; Patel, C.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save